Pharsight

Nubeqa is owned by Bayer Healthcare.

Nubeqa contains Darolutamide.

Nubeqa has a total of 8 drug patents out of which 0 drug patents have expired.

Nubeqa was authorised for market use on 30 July, 2019.

Nubeqa is available in tablet;oral dosage forms.

Nubeqa can be used as treatment of patients with non-metastatic castration resistant prostate cancer.

Drug patent challenges can be filed against Nubeqa from 2023-07-31.

The generics of Nubeqa are possible to be released after 27 February, 2038.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8975254	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (7 years from now)
US9657003	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (7 years from now)
US11046713	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (7 years from now)
US10711013	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (7 years from now)
US10383853	BAYER HEALTHCARE	Carboxamide derivative and its diastereomers in stable crystalline form	Jan, 2036 (12 years from now)
US10010530	BAYER HEALTHCARE	Carboxamide derivative and its diastereomers in stable crystalline form	Jan, 2036 (12 years from now)
US11168058	BAYER HEALTHCARE	Manufacture of a crystalline pharmaceutical product	Feb, 2038 (14 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515	BAYER HEALTHCARE	Carboxamide derivative and its diastereomers in stable crystalline form	Jan, 2036 (12 years from now)